Effect of Comp on Colorectal Cancer Cell Migration
Authors: 
Haoyu Tian, Meitong Zhou, Dongcheng Qin, Dewang Wu, Fengchen Liu, Dandan Zhang, Xiaoshuai Ren, Jun ZhouAuthors Info & Claims
Pages 5 - 12
Abstract
A publicly accessible online database was utilized in this study to investigate COMP, which is aberrantly expressed in a range of malignancies. It was discovered that colorectal cancer had significant levels of COMP expression. This finding was corroborated by Western Blot and RT-qPCR analysis tests on colorectal cancer cell lines. In order to study the effect of COMP on colorectal cancer migration, we investigated the expression of mRNA and protein levels in colorectal cancer cell lines knocked down by COMP, and the effect of COMP on the migration of SW480 cell line was studied using Transwell, wound healing assay. The findings demonstrated that the migration of colorectal cancer cell lines was suppressed by COMP expression knockdown. These findings offer a theoretical foundation for the use of COMP as a novel clinical treatment target and possible marker for the identification of colorectal cancer metastases.
References
[1]
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. 2017. Colorectal cancer statistics, 2017. CA Cancer J Clin. 67. 3, 177-193. (May 6, 2017), 177-193. http://doi.org/10.3322/caac.21395
[2]
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. 2019. Colorectal cancer. Lancet. 394. 10207, 1467-1480. (Oct 19, 2019), 1467-1480. http://doi.org/10.1016/S0140-6736(19)32319-0
[3]
Martinez-Useros J, Garcia-Foncillas J. 2016. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med. 14. 21. (Jan 22, 2016), 21. http://doi.org/10.1186/s12967-016-0772-5
[4]
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. 2012. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 23. 10, 2479-2516. (Oct, 2012), 2479-2516. http://doi.org/10.1093/annonc/mds236
[5]
Diaz LA, Jr., Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fourchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zhong WY, Fogelman D, Marinello P, Andre T, Investigators K-. 2022. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23. 5, 659-670. (May, 2022), 659-670. http://doi.org/10.1016/S1470-2045(22)00197-8
[6]
Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA, Jr. 2019. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 16. 6, 361-375. (Jun, 2019), 361-375. http://doi.org/10.1038/s41575-019-0126-x
[7]
Briggs MD, Wright MJ. COMP-Related Pseudoachondroplasia. In: GeneReviews((R)). Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, (editors). Seattle (WA); 1993.
[8]
Guo B, Wang Y, Liu W, Zhang S. 2023. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. Clin Transl Oncol. 25. 2, 535-554. (Feb, 2023), 535-554. http://doi.org/10.1007/s12094-022-02968-8
[9]
Nfonsam VN, Jecius HC, Janda J, Omesiete PN, Elquza E, Scott AJ, Nfonsam LE, Jandova J. 2020. Cartilage oligomeric matrix protein (COMP) promotes cell proliferation in early-onset colon cancer tumorigenesis. Surg Endosc. 34. 9, 3992-3998. (Sep, 2020), 3992-3998. http://doi.org/10.1007/s00464-019-07185-z
[10]
Ma H, Qiu Q, Tan D, Chen Q, Liu Y, Chen B, Wang M. 2022. The Cancer-Associated Fibroblasts-Related Gene COMP Is a Novel Predictor for Prognosis and Immunotherapy Efficacy and Is Correlated with M2 Macrophage Infiltration in Colon Cancer. Biomolecules. 13. 1, (Dec 28, 2022), http://doi.org/10.3390/biom13010062
[11]
Zhong W, Hou H, Liu T, Su S, Xi X, Liao Y, Xie R, Jin G, Liu X, Zhu L, Zhang H, Song X, Yang C, Sun T, Cao H, Wang B. 2020. Cartilage Oligomeric Matrix Protein promotes epithelial-mesenchymal transition by interacting with Transgelin in Colorectal Cancer. Theranostics. 10. 19, 8790-8806. 2020), 8790-8806. http://doi.org/10.7150/thno.44456
[12]
Blom AM, Gialeli C, Hagerling C, Berntsson J, Jirstrom K, Papadakos KS. 2023. Expression of Cartilage Oligomeric Matrix Protein in colorectal cancer is an adverse prognostic factor and correlates negatively with infiltrating immune cells and PD-L1 expression. Front Immunol. 14. 1167659. 2023), 1167659. http://doi.org/10.3389/fimmu.2023.1167659
[13]
Wusterbarth E, Chen Y, Jecius H, Krall E, Runyan RB, Pandey R, Nfonsam V. 2022. Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival. J Surg Res. 270. 169-177. (Feb, 2022), 169-177. http://doi.org/10.1016/j.jss.2021.09.007
[14]
Lee AS, Sung MJ, Kim W, Jung YJ. 2018. COMP-angiopoietin-1 ameliorates inflammation-induced lymphangiogenesis in dextran sulfate sodium (DSS)-induced colitis model. J Mol Med (Berl). 96. 5, 459-467. (May, 2018), 459-467. http://doi.org/10.1007/s00109-018-1633-x
[15]
Metharom P, Berndt MC. 2015. COMP: an endogenous thrombin inhibitor. Blood. 126. 7, 831-832. (Aug 13, 2015), 831-832. http://doi.org/10.1182/blood-2015-06-650846
[16]
Rong Z, Zheng K, Chen J, Jin X. 2024. The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer. J Cancer Res Clin Oncol. 150. 3, 154. (Mar 23, 2024), 154. http://doi.org/10.1007/s00432-024-05659-9
[17]
El-Deek HEM, El-Naggar MS, Morsy AMM, Sedik MF, Osman HA, Ahmed AM. 2024. P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer. Med Mol Morphol. (Mar 24, 2024), http://doi.org/10.1007/s00795-024-00385-0
[18]
Rumpold H, Niedersuss-Beke D, Heiler C, Falch D, Wundsam HV, Metz-Gercek S, Piringer G, Thaler J. 2020. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer. 20. 1, 1149. (Nov 25, 2020), 1149. http://doi.org/10.1186/s12885-020-07656-w
[19]
Xie YH, Chen YX, Fang JY. 2020. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 5. 1, 22. (Mar 20, 2020), 22. http://doi.org/10.1038/s41392-020-0116-z
[20]
Zhang Y, Rajput A, Jin N, Wang J. 2020. Mechanisms of Immunosuppression in Colorectal Cancer. Cancers (Basel). 12. 12, (Dec 20, 2020), http://doi.org/10.3390/cancers12123850
Index Terms
- Effect of Comp on Colorectal Cancer Cell Migration
Recommendations
The m6A reader HNRNPC predicts adverse prognosis and promotes the progression of colorectal cancer
BACKGROUND:As a critical m6A RNA methylation regulator, HNRNPC has been revealed to serve as potential biomarkers in various human cancers. The specific expression and significance of HNRNPC in colorectal cancer remain unknown.
OBJECTIVE:This ...
Predictive Value of CD3, CD8, CD45RO Expression in Stage II/III Colorectal Cancer: Enhancing Predictive Value and Quality of Diagnosis
This article describes how colorectal carcinomas CRC are the fourth most frequently diagnosed cancer. However, despite advances in specific treatment, approximately 40% to 50% of patients have disease recurrence following potentially curative surgery, ...
A review of Colorectal Cancer and Intestinal Microbiota
ICBBS '21: Proceedings of the 2021 10th International Conference on Bioinformatics and Biomedical ScienceIn 2020, around ten million people worldwide were diagnosed with cancer. Being one of the leading causes of death, cancer contributes to a large portion of annual deaths globally. Among them, one of the most common cancers, colorectal cancer, caused ...
Comments
Please enable JavaScript to view thecomments powered by Disqus.Information & Contributors
Information
Published In
June 2024
241 pages
ISBN:9798400717628
DOI:10.1145/3678935
Copyright © 2024 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than the author(s) must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected].
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 12 October 2024
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Funding Sources
Conference
ICBET 2024
ICBET 2024: 2024 14th International Conference on Biomedical Engineering and Technology
June 14 - 17, 2024
Seoul, Republic of Korea
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 7Total Downloads
- Downloads (Last 12 months)7
- Downloads (Last 6 weeks)4
Reflects downloads up to 18 Dec 2024
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format